Anemia represents the most common hematologic deficit affecting patients with myelodysplastic syndrome (MDS), and contributes to morbidity and mortality over time through complications related to iron overload. 1 Development of new therapeutics for MDS has been challenged by the difficulty in identifying pathogenetically relevant targets that contribute to ineffective erythropoiesis. Clonogenic response to erythropoietin (EPO) is impaired in MDS despite normal cytokine receptor display and intact ligand binding capacity. EPO receptor activation of the signal transduction and activator of transcription (STAT)-5 and globin transcription factor 1 (GATA-1) is impaired in myelodysplastic erythroid progenitors supporting an intrinsic disturbance in receptor-signal transduction. 2 Indeed, despite preserved proliferative response to EPO, apoptosis supercedes with differentiation, exacerbated in part by hematopoietic inhibitory cytokines within the marrow microenvironment. 3 The EPO receptor is a class I cytokine receptor that lacks intrinsic kinase activity, and thereby signals through the activation of constitutively associated cytoplasmic tyrosine kinases such as the janus tyrosine kinase-2 (Jak2). 4 Ligandinduced conformational change in the EPO receptor homodimer activates Jak2 phosphorylation of tyrosine residues on the receptor cytoplasmic tail, which serve as docking sites for adaptor proteins and the consequent recruitment of the STAT5a/ b transcription factors to the signaling platform. 5 Upon phosphorylation by Jak2, STAT5 homodimerizes and translocates to the nucleus, where it activates transcription of genes controlling the proliferation and survival of erythroid cells as well as negative regulators of the cytokine signal. Included among the latter is the suppressors of cytokine signaling (SOCS) gene family, which is comprised of eight members that share a central Src homology-2 (SH2) domain, a conserved carboxy-terminal sequence termed the SOCS box, and a variable N-terminus (reviewed by Kile and Alexander 6 ). Transient activation of SOCS-3, also known as STAT-induced STAT inhibitor-3 (SSI-3) or cytokine-induced SH2 protein 3 (CIS3), plays a key regulatory role in EPO signal attenuation in addition to other cytokine receptors. Indeed, the SOCS-3 null phenotype is embryonically lethal at days 12-16 owing to excessive erythrocytosis, whereas transgene-forced expression of SOCS-3 blocks fetal erythropoiesis while increasing in vitro proliferation of primitive erythroid progenitors. SOCS-3 is constitutively expressed in transformed erythroleukemia cell lines where its expression has been implicated in the maturation arrest and impaired differentiation capacity. Constitutive expression of SOCS-3 has been reported in other human malignancies such as cutaneous T-cell lymphoma, and in chronic myeloid leukemia (CML) where it is believed to contribute to interferon resistance. 6 To evaluate the contribution of SOCS-3 to the ineffective hematopoiesis in MDS, we investigated SOCS-3 gene expression and protein localization in MDS patient specimens. We found that SOCS-3 is constitutively expressed in myelodysplastic erythroid precursors.
Bone marrow specimens were obtained following informed consent from patients with MDS or healthy volunteers at the Arizona Cancer Center, Tucson, AZ, USA according to the institutional review board guidelines. Additional normal volunteer marrow aspirates were purchased from Clonetics (Walkersville, MD, USA). Whole mononuclear cells (WMN) were obtained by density-gradient centrifugation using Ficoll-Hypaque (Sigma, St Louis, MO, USA).
RNA was isolated from bone marrow WMN cells or from enriched cells described above using the GeneElute Mammalian Total RNA Miniprep kit (Sigma, St Louis, MO, USA) according to the manufacturer's protocol. Residual genomic DNA was removed using Ambion's DNA free kit (Ambion, Austin, TX, USA). The concentration of total cellular RNA was quantified by measuring the optical density at 260 nm (OD260).
The SOCS-3 primers and probe were designed using the Primer Express software program 2.0 (PE Applied Biosystems, Foster City, CA, USA). SOCS-3 forward primer was 5 0 -CTCAAGACCTTCAGCTCCAAGAG-3 0 and reverse primer was 5 0 -GGTCACTGCGCTCCAGTAGAA-3 0 . The SOCS-3 probe was labeled with 6-carboxy-fluorescein (FAM) dye reporter at the 5 0 end and a 6-carboxy-tetramethyl-rhodamine quencher (TAM-RA) at the 3' end. The probe sequence was 5 0 -(FAM) TGGTGAACGCAGTGCGCAAGC-(TAMRA)-3 0 . Reverse transcriptase-polymerase chain rection (RT-PCR) was performed using PE Biosystems PCR core reagent kit. A pre-optimized probe/primer set (Assays on Demand, Applied Biosystems, Foster City, CA, USA) was used for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Quantitative real-time RT-PCR was performed using a PE Biosystems GeneAmp 5700 sequence detection system. The RT reaction was performed at 481C for 30 min. Following RT incubation, samples were heated 10 min at 951C with subsequent amplification for 15 s at 951C followed by 1 min at 601C for 40 cycles. Values were normalized to GAPDH and quantitated using the delta cycle threshold method. Results were expressed relative to 'normal' bone marrow. Immunohistochemical (IHC) staining for SOCS-3 was performed on formalin-fixed, paraffin-embedded bone marrow trephine biopsies using a polyclonal antibody (Zymed Laboratories, South San Francisco, CA, USA). Detection of bound antibody was assessed using immunoperoxidase methodologies with diaminobenzidine as the color substrate. Endogenous peroxidase was inhibited with methyl alcohol containing 0.01% H 2 O 2 . All reactions were performed using an automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA). An isotype-matched irrelevant antibody diluted in the VMS antibody diluent and incubated with tissue sections served as a negative control. Nuclei were counter-stained with hematoxylin and sections evaluated by light microscopy. The degree of expression in tumor cells was judged at Â 400 magnification as 4 þ (very intensely positive), 3 þ (moderately intensely positive), 2 þ (moderate), 1 þ (faint) or 0 (completely negative) throughout the sample.
A total of 38 MDS (French-American-British (FAB) specimens including refractory anemia (RA) (N ¼ 16), refractory anemia with ringed sideroblast (RARS) (N ¼ 8), refractory anemia with excess blasts (RAEB) (N ¼ 10) and refractory anemia excess blasts-in transformation (RAEB-t) (N ¼ 2), MDS with deletion 5q (N ¼ 2)) and 16 normal samples were analyzed by quantitative RT-PCR. SOCS-3 gene message was higher in MDS samples compared to normal bone marrow, although the difference did not reach statistical significance using a Student's t-test. (P ¼ 0.85) (Figure 1 ). The level of SOCS-3 gene expression varied widely among MDS cases, perhaps reflecting bias imposed by analysis of marrow mononuclear cells comprising a mixed lineage cell population at varied stages of differentiation.
IHC staining for SOCS-3 protein was performed on trephine core biopsies from 25 patients, including the following FAB subtypes: 13 RA, eight RAEB and five RARS. There was no concordance between SOCS-3 mRNA and protein expression in MDS, except in specimens with low SOCS-3 protein expression (0/ þ ), which displayed significantly lower gene message levels (P ¼ 0.015). In all cases examined by IHC, SOCS-3 staining was localized almost exclusively in erythroid precursors in a cytoplasmic and nuclear distribution, with weak or absent staining in other lineages (Figure 2 ). Nine trephine core biopsies from normal volunteers were evaluated by IHC, which revealed minimal detectable SOCS-3 staining in erythroid precursors or other marrow elements, indicating that upregulation of SOCS-3 in the erythroid compartment is specific to MDS. No discernable differences were observed in the pattern of gene or protein expression among FAB morphologic types. However, given the relatively small sample size, we cannot exclude possible differences among morphologic types.
Our investigations indicate that SOCS-3 gene message and protein expression is constitutively upregulated in erythroid precursors in MDS compared to normal bone marrow. SOCS-3 undergoes tyrosyl phosphorylation by the serine/threonine kinase Pim-1 in response to EPO, resulting in stabilization of the SOCS-3 protein, which may participate in the sustained expression in MDS erythroid precurors. 7 More recently, casein kinase Iå has been shown to stabilize the SOCS-3 protein in murine myeloid progenitor cells. 8 These findings suggest that SOCS-3 overexpression may contribute to ineffective erythropoiesis in MDS and merits further investigation. 
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Figure 2
Comparison of SOCS-3 protein in normal and MDS bone marrow. IHC staining of trephine core biopsies from patients with normal bone marrow or MDS with corresponding isotype controls. Photomicrograph of the MDS specimen shows strong SOCS-3 expression in erythroid precursors.
